CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 397 filers reported holding CRISPR THERAPEUTICS AG in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,539 | -19.1% | 100 | 0.0% | 0.00% | 0.0% |
Q2 2023 | $5,614 | +24.1% | 100 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $4,523 | -13.1% | 100 | -21.9% | 0.00% | 0.0% |
Q4 2022 | $5,203 | -35.0% | 128 | 0.0% | 0.00% | -33.3% |
Q3 2022 | $8,000 | 0.0% | 128 | 0.0% | 0.01% | 0.0% |
Q2 2022 | $8,000 | 0.0% | 128 | +2.4% | 0.01% | +20.0% |
Q1 2022 | $8,000 | -11.1% | 125 | 0.0% | 0.01% | -16.7% |
Q4 2021 | $9,000 | -35.7% | 125 | 0.0% | 0.01% | -40.0% |
Q3 2021 | $14,000 | -30.0% | 125 | 0.0% | 0.01% | -28.6% |
Q2 2021 | $20,000 | +33.3% | 125 | 0.0% | 0.01% | +16.7% |
Q1 2021 | $15,000 | -92.5% | 125 | -90.4% | 0.01% | -92.9% |
Q4 2020 | $199,000 | – | 1,299 | – | 0.17% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |